Published in MAbs on August 05, 2016
Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis. EBioMedicine (2017) 0.82
Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A (2017) 0.77
Antibody Glycosylation Predicts Relapse in Autoimmune Vasculitis. EBioMedicine (2017) 0.75
Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering. Sci Rep (2017) 0.75
Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev Rheumatol (2017) 0.75
Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI. Sci Rep (2017) 0.75
Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics (2017) 0.75
Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs (2017) 0.75
The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J (1959) 31.27
Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys (1960) 13.40
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry (1981) 6.13
Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature (1985) 5.32
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature (2000) 3.53
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol (2003) 3.25
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Rituximab: mechanism of action. Semin Hematol (2010) 2.66
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci U S A (1983) 2.33
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates. Anal Biochem (1992) 1.86
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem (2005) 1.85
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol (2012) 1.70
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology (2006) 1.69
NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry (2012) 1.60
Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol (2004) 1.59
Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta (2005) 1.56
Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet (2013) 1.52
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 1.48
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem (2001) 1.48
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. PLoS Pathog (2016) 1.43
Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol (2013) 1.36
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood (2013) 1.34
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol (2011) 1.30
Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry (2009) 1.25
Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U S A (2013) 1.17
High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res (2013) 1.16
Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol (2011) 1.15
Amine coupling through EDC/NHS: a practical approach. Methods Mol Biol (2010) 1.12
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica (2012) 1.09
Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep (2014) 1.06
Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci U S A (2013) 1.00
Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis (2015) 1.00
Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc (2013) 0.96
The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure (2015) 0.95
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol (2015) 0.95
The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology (2008) 0.95
Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A (2015) 0.94
Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol (2014) 0.92
A global benchmark study using affinity-based biosensors. Anal Biochem (2008) 0.91
Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs (2013) 0.88
Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene. J Biol Chem (2012) 0.88
Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding. Structure (2014) 0.86
Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions. J Proteome Res (2014) 0.86
High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension. J Vis Exp (2015) 0.80
Three major uncertainties in the antibody therapy of cancer. Haematologica (2014) 0.80
Structure and function of immunoglobulins. Acta Endocrinol Suppl (Copenh) (1975) 0.78
Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia. J Adv Pract Oncol (2015) 0.76
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. Ther Adv Hematol (2016) 0.76